Evidence map›Paper›PMID 41132685›Full record

ArticleFrontiers in immunology2025

A crucial role of the malate aspartate shuttle in metabolic reprogramming in TNF-induced SIRS.

Louise Nuyttens, Marah Heyerick, Maxime Roes, Elise Moens, Céline Van Dender, Charlotte Wallaeys, Tino Hochepied, Steven Timmermans, Jolien Vandewalle, Claude Libert

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Louise NuyttensCenter for Inflammation Research, Vlaams Instituut Voor Biotechnologie (VIB), Ghent, Belgium.
Marah HeyerickCenter for Inflammation Research, Vlaams Instituut Voor Biotechnologie (VIB), Ghent, Belgium.
Maxime RoesCenter for Inflammation Research, Vlaams Instituut Voor Biotechnologie (VIB), Ghent, Belgium.
Elise MoensCenter for Inflammation Research, Vlaams Instituut Voor Biotechnologie (VIB), Ghent, Belgium.
Céline Van DenderCenter for Inflammation Research, Vlaams Instituut Voor Biotechnologie (VIB), Ghent, Belgium.
Charlotte WallaeysCenter for Inflammation Research, Vlaams Instituut Voor Biotechnologie (VIB), Ghent, Belgium.
Tino HochepiedCenter for Inflammation Research, Vlaams Instituut Voor Biotechnologie (VIB), Ghent, Belgium.
Steven TimmermansCenter for Inflammation Research, Vlaams Instituut Voor Biotechnologie (VIB), Ghent, Belgium.
Jolien VandewalleCenter for Inflammation Research, Vlaams Instituut Voor Biotechnologie (VIB), Ghent, Belgium.
Claude LibertCenter for Inflammation Research, Vlaams Instituut Voor Biotechnologie (VIB), Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor (TNF) causes a lethal systemic inflammatory response syndrome (SIRS) which is characterized by significant metabolic alterations. Based on liver RNA sequencing, we found that TNF impairs the malate-aspartate shuttle (MAS), an essential redox shuttle that transfers reducing equivalents across the inner mitochondrial membrane thereby recycling cytosolic NAD

Indexed as

Aspartic AcidMalatesSystemic Inflammatory Response SyndromeTumor Necrosis Factor-alphaAnimalsGlycolysisLiverMaleMetabolic ReprogrammingMiceMice, Inbred C57BLMice, KnockoutMitochondriaMitochondrial Membrane Transport ProteinsNADAspartic AcidMalatesmalic acidMitochondrial Membrane Transport ProteinsNADTumor Necrosis Factor-alphacarbohydrate metabolismcitrinlipid metabolismmalate aspartate shuttleTNF-induced SIRS

Identifiers

PMID41132685
PMCPMC12542566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.